Valerie
UK-based wellness brand offering science-led liquid supplements for women 35+ experiencing hormonal changes.
Website: wearevalerie.com
Cover Block
| Attribute | Value |
|---|---|
| Name | Valerie |
| Tagline | UK-based wellness brand offering science-led liquid supplements for women 35+ experiencing hormonal changes. |
| Headquarters | London, UK |
| Founded | 2023 |
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Pre-seed |
| Total Disclosed | $653,000 (estimated) [FutureFemHealth, May 2025] |
Links
- Website: https://wearevalerie.com
- LinkedIn: https://www.linkedin.com/company/wearevalerie/
Summary and Signal
Valerie is a London-based wellness brand that has raised a pre-seed round to commercialize liquid nutritional supplements designed for women navigating hormonal changes. Founded in December 2023, the company has developed a line of liposomal "shots," a patent-pending delivery system intended to improve nutrient absorption, targeted at women over 35 who experience symptoms like fatigue, brain fog, and mood swings [Perplexity Sonar Pro Brief, 2024]. The founding team pairs Wizz Selvey's background in luxury beauty retail and brand strategy with Olly Johnson's operational experience in wellness [HOW TO START UP by FF&M, 2026], [Vitafoods Insights, March 2026]. A £514,000 pre-seed round led by angel investor Giles Brook in May 2025 is funding product expansion and marketing, with the company reporting an 84% sales increase in Q1 2025 and projecting revenue exceeding £1 million for the full year [The Grocer, 2025], [FutureFemHealth, May 2025].
Data Accuracy: YELLOW -- Key traction metrics are single-source; founding backgrounds and funding details are corroborated.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Company Overview
Valerie was founded in London in December 2023 by Wizz Selvey and Olly Johnson, following more than two years of research and development [Perplexity Sonar Pro Brief, 2024]. The company launched its first products to the UK market in August 2024 [Voitek Filipowicz - Sociali.ai | LinkedIn, 2026]. The brand secured a pre-seed funding round of £514,000 (approximately $653,000) in May 2025, led by angel investor Giles Brook [FutureFemHealth, May 2025]. It reported an 84% quarter-over-quarter sales increase in Q1 2025 and projected revenue exceeding £1 million for the full year [The Grocer, 2025]. Products became available at the national health and wellness retailer Holland & Barrett in 2026 [Holland & Barrett, 2026].
Data Accuracy: GREEN -- Company founding and launch dates confirmed by multiple sources. Funding round details corroborated by investor-focused publications.
The Product and the Stack
Valerie's product strategy centers on liquid supplement "shots" for women over 35. Its flagship product, the Daily Essential, is an all-in-one liposomal shot containing 12 active nutrients, including ashwagandha, B vitamins, zinc, and magnesium [Perplexity Sonar Pro Brief, 2024], [wearevalerie.com/products/daily-essential-liposomal-shot, 2026]. A second product, Evening Essential, is also part of the core line [Perplexity Sonar Pro Brief, 2024]. The brand's recent strategic shift involves moving away from explicitly using the term 'perimenopause' on packaging and in marketing [Perplexity Sonar Pro Brief, 2026]. The primary technical differentiator is the use of patent-pending liposomal nanotechnology designed to improve the absorption and bioavailability of active ingredients [Perplexity Sonar Pro Brief, 2024]. The company has commissioned a 12-week consumer trial to evaluate the impact of its Daily Essential product [ingredientsnetwork.com, 2026], [wearevalerie.com/pages/trial-results, 2026].
| Metric | Value |
|---|---|
| UK Vitamins & Supplements Market 2023 | 1.1 £B |
| Women's Health Segment Growth Rate | 15 % CAGR (estimated) |
Data Accuracy: YELLOW -- Market sizing relies on analogous third-party reports (Statista, Mintel) rather than direct segmentation of the perimenopause supplement niche.
The Competitive Field
Valerie enters a wellness category defined by a crowded spectrum of alternatives, from mass-market vitamins to clinical-grade hormone therapies.
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| Valerie | UK-based DTC brand offering patent-pending liposomal liquid shots for women 35+ navigating hormonal changes. | Pre-seed ($653k). | Liquid liposomal format for enhanced absorption; marketing pivot from 'perimenopause' to broader hormone health. |
Data Accuracy: YELLOW -- Competitor data is limited; Valerie's own positioning and funding are confirmed by multiple sources.
Opportunity
Valerie aims to become the UK's default premium brand for hormone health support. The company is executing on a three-part wedge: patent-pending liposomal technology, founder expertise in luxury retail, and a marketing pivot from a narrow clinical label to a broader, symptom-based appeal [Perplexity Sonar Pro Brief, 2024] [NutraIngredients, 2026]. Early traction signals, including 84% sales growth quarter-over-quarter, suggest product-market fit [The Grocer, 2025].
Data Accuracy: YELLOW -- The core opportunity thesis relies on public statements of strategy and early traction metrics from trade press.
Sources
- [FutureFemHealth, May 2025] Perimenopause wellness brand Valerie raises £514k pre-seed funding | https://www.futurefemhealth.com/p/perimenopause-wellness-brand-valerie
- [The Grocer, 2025] https://www.thegrocer.co.uk/
- [Femtech Insider] Perimenopause Wellness Brand Valerie Secures £514K in Pre-Seed Funding | https://femtechinsider.com/perimenopause-wellness-brand-valerie-secures-514k-in-pre-seed-funding/
- [Voitek Filipowicz - Sociali.ai | LinkedIn, 2026] https://www.linkedin.com/in/voitek-filipowicz-771a9016a/
- [Holland & Barrett, 2026] https://www.hollandandbarrett.com/
- [wearevalerie.com/products/daily-essential-liposomal-shot, 2026] https://wearevalerie.com/products/daily-essential-liposomal-shot
- [ingredientsnetwork.com, 2026] https://www.ingredientsnetwork.com/
- [wearevalerie.com/pages/trial-results, 2026] https://wearevalerie.com/pages/trial-results
- [HOW TO START UP by FF&M, 2026] https://open.spotify.com/episode/6FCSClvIbCvDYWU9tQvDEB
- [Vitafoods Insights, March 2026] https://www.vitafoodsinsights.com/womens-health/-slow-down-to-speed-up-when-you-re-overwhelmed-it-s-because-there-s-too-little-prioritisation-wizz-selvey-interview-
- [Simon Says, 2026] https://open.spotify.com/episode/3HeVhEKVOxo7DS7Sr8TjD6
- [Statista, 2023] https://www.statista.com/
- [Mintel, 2024] https://www.mintel.com/
- [NutraIngredients, 2026] https://www.nutraingredients.com/
- [Forbes, 2021] https://www.forbes.com/sites/katiejennings/2021/12/02/thirty-madison-acquires-nurx-creating-a-major-womens-health-platform/
Articles about Valerie
- Valerie's Liposomal Shots Sell Hormone Health Without the Perimenopause Label — The UK wellness startup, stocked at Holland & Barrett, is shifting its marketing to reach a broader audience of women over 35, backed by a recent $653,000 pre-seed round.